Q3 FY2026 · ended Sep 30, 2026 · Revenue $13.83M, -5.8% YoY · Filed Nov 5, 2026
CVRx, Inc. (CVRX) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $13.8 million and a net loss of $14.2 million. Free cash flow was -$11.0 million. As of Sep 30, 2026 it held $58.7 million in cash and investments and $59.4 million in total debt.
Revenue
$13.83M
-5.8% vs year-ago quarter
Net income
$-14.16M
-10.0% vs year-ago quarter
Operating cash flow
$-10.90M
-12.2% vs year-ago quarter
Free cash flow
$-10.99M
-9.9% vs year-ago quarter
EPS
$-0.52
-6.1% vs year-ago quarter
Dividend per share
None
Shares outstanding
28.49M
+8.7% vs year-ago quarter
Net cash
$-639,000
Q3 FY2026
Operating margin
-81.9%
TTM
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- CVRX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Minneapolis, MN
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1235912
- Former names
- CVRX INC (until Jul 15, 2013)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $13.8M | $15.7M | $14.8M | $16.0M | $14.7M |
| Operating income | -$13.0M | -$13.0M | -$12.2M | -$11.2M | -$12.3M |
| Net income | -$14.2M | -$14.0M | -$13.1M | -$11.9M | -$12.9M |
| Diluted EPS | -$0.52 | -$0.53 | -$0.50 | -$0.46 | -$0.49 |
| Operating cash flow | -$10.9M | -$8.8M | -$12.2M | -$9.8M | -$9.7M |
| Free cash flow | -$11.0M | -$8.9M | -$12.3M | -$9.8M | -$10.0M |
| Total assets | $87.6M | $92.3M | $99.7M | $104.8M | $111.3M |
| Total liabilities | $73.8M | $72.3M | $70.6M | $65.5M | $63.3M |
| Stockholders' equity | $13.8M | $20.0M | $29.1M | $39.3M | $48.1M |
| Cash and investments | $58.7M | $64.6M | $72.3M | $75.7M | $85.1M |
| Total debt | $59.4M | $59.4M | $59.4M | $50.5M | $50.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 21, 2026 | Sep 16, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 11, 2026 | Aug 10, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
All 348 CVRx, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.